BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol 2014;167:394-401. [PMID: 25066629 DOI: 10.1111/bjh.13040] [Cited by in Crossref: 89] [Cited by in F6Publishing: 69] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Chantada G, Lam CG, Howard SC. Optimizing outcomes for children with non‐Hodgkin lymphoma in low‐ and middle‐income countries by early correct diagnosis, reducing toxic death and preventing abandonment. Br J Haematol 2019;185:1125-35. [DOI: 10.1111/bjh.15785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol 2019;185:1071-85. [PMID: 30613948 DOI: 10.1111/bjh.15734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
3 Santiago R, Vairy S, Sinnett D, Krajinovic M, Bittencourt H. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother 2017;18:1081-99. [PMID: 28608730 DOI: 10.1080/14656566.2017.1340938] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
4 Garciaz S, Coso D, Brice P, Bouabdallah R. [Hodgkin and non-Hodgkin lymphoma of adolescents and young adults]. Bull Cancer 2016;103:1035-49. [PMID: 27866679 DOI: 10.1016/j.bulcan.2016.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Wilkie GL, Taggart AA, Prensner JR, Billett AL, Laufer MR. Burkitt Lymphoma Presenting as Menorrhagia and a Vaginal Mass in an Adolescent. Journal of Pediatric and Adolescent Gynecology 2019;32:90-2. [DOI: 10.1016/j.jpag.2018.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Lange J, Lenz G, Burkhardt B. Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications. Expert Rev Hematol 2017;10:123-35. [PMID: 27936978 DOI: 10.1080/17474086.2017.1271318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Moleti ML, Testi AM, Foà R. Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries. Br J Haematol 2021. [PMID: 34866182 DOI: 10.1111/bjh.17979] [Reference Citation Analysis]
8 Sandlund JT, Guillerman RP, Perkins SL, Pinkerton CR, Rosolen A, Patte C, Reiter A, Cairo MS. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol 2015;33:2106-11. [PMID: 25940725 DOI: 10.1200/JCO.2014.59.0745] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 5.6] [Reference Citation Analysis]
9 Aydin B, Akyuz C, Kalkan N, Kurucu N, Varan A, Yalcin B, Kutluk T. FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience. J Pediatr Hematol Oncol 2019;41:e7-e11. [PMID: 30059355 DOI: 10.1097/MPH.0000000000001270] [Reference Citation Analysis]
10 Cairo MS. Rituximab in the treatment of childhood mature B-cell lymphoma: "Where do we go from here". Br J Haematol 2019;185:1017-20. [PMID: 31115041 DOI: 10.1111/bjh.15940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Lee S, Day NS, Miles RR, Perkins SL, Lim MS, Ayello J, van de Ven C, Harrison L, El-Mallawany NK, Goldman S, Cairo MS. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol 2017;177:601-11. [PMID: 28474336 DOI: 10.1111/bjh.14604] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
12 Goel AN, Filimonov A, Teruya-Feldstein J, Salib C, Rousso JJ, Hackett AM, Rothschild MA, Wanna GB. Burkitt lymphoma of the nasopharynx causing life-threatening airway obstruction: A case report. Am J Otolaryngol 2021;42:102977. [PMID: 33636684 DOI: 10.1016/j.amjoto.2021.102977] [Reference Citation Analysis]
13 Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Reiter A, Cairo MS. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 2015;33:2112-8. [PMID: 25940716 DOI: 10.1200/JCO.2014.59.7203] [Cited by in Crossref: 84] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
14 Lee S, Luo W, Shah T, Yin C, O'Connell T, Chung TH, Perkins SL, Miles RR, Ayello J, Morris E, Harrison L, van de Ven C, Cairo MS. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. Oncotarget 2017;8:27839-53. [PMID: 28427156 DOI: 10.18632/oncotarget.15711] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
15 Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel) 2015;7:305-28. [PMID: 25643241 DOI: 10.3390/cancers7010305] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
16 Geerlinks A, Keis J, Ngan B, Shammas A, Vali R, Hitzler J. Unusual lymphoid malignancy and treatment response in two children with Down syndrome. Pediatr Blood Cancer 2019;66:e27822. [PMID: 31136091 DOI: 10.1002/pbc.27822] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Hochberg J, Cairo MS. Lymphoma in Adolescents and Young Adults: Current Perspectives. Cancer J 2018;24:285-300. [PMID: 30480573 DOI: 10.1097/PPO.0000000000000345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Sorge CE, McDaniel JK, Xavier AC. Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals (Basel) 2016;9:E28. [PMID: 27213405 DOI: 10.3390/ph9020028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Shah NN. Antibody Based Therapies in Acute Leukemia. Curr Drug Targets 2017;18:257-70. [PMID: 27593687 DOI: 10.2174/1389450117666160905091459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Voss SD, Cairo MS. Surveillance imaging in pediatric lymphoma. Pediatr Radiol 2019;49:1565-73. [PMID: 31620855 DOI: 10.1007/s00247-019-04511-4] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chu Y, Yahr A, Huang B, Ayello J, Barth M, S Cairo M. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology 2017;6:e1341031. [PMID: 28932644 DOI: 10.1080/2162402X.2017.1341031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
22 Xiao Z, Mo Y, Long W, Li R, Li X, Wei Y, Fan W, Zhang X. Value of baseline and end of chemotherapy 18F-FDG PET/CT in pediatric patients with Burkitt lymphoma. Leuk Lymphoma 2021;62:2873-81. [PMID: 34165390 DOI: 10.1080/10428194.2021.1941933] [Reference Citation Analysis]
23 Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology 2019;8:e1512455. [PMID: 30546948 DOI: 10.1080/2162402X.2018.1512455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Zhu J, Zhen Z, Wang J, Sun F, Lu S, Huang J, Zhang Y, Sun X. Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children. Pediatr Investig 2021;5:112-7. [PMID: 34179707 DOI: 10.1002/ped4.12260] [Reference Citation Analysis]
25 Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol 2015;170:367-71. [PMID: 25858645 DOI: 10.1111/bjh.13443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
26 Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol 2015;33:2963-74. [PMID: 26304908 DOI: 10.1200/JCO.2014.59.5827] [Cited by in Crossref: 131] [Cited by in F6Publishing: 51] [Article Influence: 18.7] [Reference Citation Analysis]
27 Diorio C, Teachey DT. Harnessing immunotherapy for pediatric T-cell malignancies. Expert Rev Clin Immunol 2020;16:361-71. [PMID: 32103690 DOI: 10.1080/1744666X.2020.1732819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
28 Jastaniah W. Successful treatment of mature B-cell lymphoma with rituximab-based chemotherapy in a patient with Bloom syndrome. Pediatr Blood Cancer 2017;64. [PMID: 27966805 DOI: 10.1002/pbc.26385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
29 Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program 2016;2016:589-97. [PMID: 27913533 DOI: 10.1182/asheducation-2016.1.589] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
30 Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res 2017;23:4212-23. [PMID: 28348046 DOI: 10.1158/1078-0432.CCR-16-2703] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
31 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
32 Bhatti M, Ippolito T, Mavis C, Gu J, Cairo MS, Lim MS, Hernandez-Ilizaliturri F, Barth MJ. Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget 2018;9:21820-30. [PMID: 29774105 DOI: 10.18632/oncotarget.25072] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
33 de Zwart V, Gouw SC, Meyer-Wentrup FA. Antibody therapies for lymphoma in children. Cochrane Database Syst Rev 2016;:CD011181. [PMID: 26784573 DOI: 10.1002/14651858.CD011181.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Mukhtar F, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, Tran TV, Zgibor JC, Luu HN. Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer 2017;140:1494-502. [PMID: 28006853 DOI: 10.1002/ijc.30576] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
35 Ozuah NW, Lubega J, Allen CE, El-Mallawany NK. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. Blood Adv 2020;4:4007-19. [PMID: 32841337 DOI: 10.1182/bloodadvances.2020002178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:2402-11. [PMID: 27080498 DOI: 10.1016/S0140-6736(15)01317-3] [Cited by in Crossref: 106] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
37 Verhoeven D, Stoppelenburg AJ, Meyer-wentrup F, Boes M. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. Clinical Immunology 2018;190:22-31. [DOI: 10.1016/j.clim.2018.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
38 Ge X, Chen J, Li L, Ding P, Wang Q, Zhang W, Li L, Lv X, Zhou D, Jiang Z, Zeng H, Xu Y, Hou Y, Hu W. Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. Cell Death Dis 2018;10:8. [PMID: 30584254 DOI: 10.1038/s41419-018-1259-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Barth MJ, Chu Y, Hanley PJ, Cairo MS. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol 2016;173:597-616. [PMID: 27062282 DOI: 10.1111/bjh.14078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
40 Saleh K, Michot JM, Camara-Clayette V, Vassetsky Y, Ribrag V. Burkitt and Burkitt-Like Lymphomas: a Systematic Review. Curr Oncol Rep 2020;22:33. [PMID: 32144513 DOI: 10.1007/s11912-020-0898-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
41 Giulino-roth L, Goldman S. Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. Br J Haematol 2016;173:531-44. [DOI: 10.1111/bjh.13969] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Chamberlain G, Coltin H, Klaassen RJ, Story E, Abbott LS. Successful treatment of pediatric primary hepatic Burkitt lymphoma using rituximab: A case report. Pediatr Blood Cancer 2021;68:e29259. [PMID: 34357676 DOI: 10.1002/pbc.29259] [Reference Citation Analysis]
43 Mussolin L, Lovisa F, Gallingani I, Cavallaro E, Carraro E, Damanti CC, Vinti L, Sala A, Micalizzi C, Santoro N, Piglione M, Cellini M, Buffardi S, Buldini B, D'Amore ESG, Biffi A, Pillon M. Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration. Br J Haematol 2020;189:e108-11. [PMID: 32080837 DOI: 10.1111/bjh.16531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Awasthi A, Rolland DCM, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Klein C, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget 2017;8:113895-909. [PMID: 29371955 DOI: 10.18632/oncotarget.23040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
45 Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol 2020;38:2519-29. [PMID: 32453640 DOI: 10.1200/JCO.20.00303] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
46 Thomas X. Novel approaches to pediatric leukemia treatment. Expert Review of Anticancer Therapy 2015;15:811-28. [DOI: 10.1586/14737140.2015.1047769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Moleti ML, Testi AM, Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2020;189:826-43. [PMID: 32141616 DOI: 10.1111/bjh.16461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Niedźwiecki M, Budziło O, Adamkiewicz-Drożyńska E, Pawlik-Gwozdecka D, Zieliński M, Maciejka-Kembłowska L, Szczepański T, Trzonkowski P. CD4+CD25highCD127low/-FoxP3 + Regulatory T-Cell Population in Acute Leukemias: A Review of the Literature. J Immunol Res 2019;2019:2816498. [PMID: 30944830 DOI: 10.1155/2019/2816498] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
49 Fu Y, Wang H, Zhai X, Qian X, Meng J, Miao H, Zhu X, Yu Y, Lu F. Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China. J Pediatr Hematol Oncol 2019;41:170-4. [PMID: 30664102 DOI: 10.1097/MPH.0000000000001419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Hochberg J, Flower A, Brugieres L, Cairo MS. NHL in adolescents and young adults: A unique population. Pediatr Blood Cancer 2018;65:e27073. [PMID: 29741220 DOI: 10.1002/pbc.27073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
51 Metzger ML, Mauz-Körholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol 2019;185:1142-57. [PMID: 30729493 DOI: 10.1111/bjh.15789] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
52 Choi JY, Kang HJ, An HY, Hong KT, Shin HY. Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients. Int J Hematol 2020;111:877-87. [PMID: 32215821 DOI: 10.1007/s12185-020-02863-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
53 Adhikari N, Biswas A, Bakhshi S, Khanna G, Suri V. A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. Childs Nerv Syst 2018;34:1777-83. [PMID: 29744624 DOI: 10.1007/s00381-018-3807-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
54 Chu Y, Nayyar G, Kham Su N, Rosenblum JM, Soon-Shiong P, Lee J, Safrit JT, Barth M, Lee D, Cairo MS. Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma. J Immunother Cancer 2020;8:e001238. [PMID: 33109629 DOI: 10.1136/jitc-2020-001238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sandlund JT. Non-Hodgkin Lymphoma in Children. Curr Hematol Malig Rep 2015;10:237-43. [DOI: 10.1007/s11899-015-0277-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
56 Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. Br J Haematol 2015;171:763-75. [DOI: 10.1111/bjh.13764] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
57 Kobos R, Terry W. Advances in therapies for non-Hodgkin lymphoma in children. Hematology 2015;2015:522-8. [DOI: 10.1182/asheducation-2015.1.522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
58 Barth MJ, Minard-Colin V. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol 2019;185:1111-24. [PMID: 30701541 DOI: 10.1111/bjh.15783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia 2021. [PMID: 33941850 DOI: 10.1038/s41375-021-01256-8] [Reference Citation Analysis]
60 Mauz-Körholz C, Ströter N, Baumann J, Botzen A, Körholz K, Körholz D. Pharmacotherapeutic Management of Pediatric Lymphoma. Paediatr Drugs 2018;20:43-57. [PMID: 29127674 DOI: 10.1007/s40272-017-0265-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
61 Cairo M, Auperin A, Perkins SL, Pinkerton R, Harrison L, Goldman S, Patte C. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol 2018;182:859-69. [PMID: 29984828 DOI: 10.1111/bjh.15491] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
62 Cairo MS, Beishuizen A. Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. Br J Haematol 2019;185:1021-42. [PMID: 30729513 DOI: 10.1111/bjh.15764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 Ni F, Huang X, Chen Z, Qian W, Tong X. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. Sci Rep 2018;8:3317. [PMID: 29463831 DOI: 10.1038/s41598-018-21570-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
64 Srinivasan S, Roy Moulik N, Kc A, Narula G, Sankaran H, Prasad M, Dhamne C, Cheriyalinkal Parambil B, Shah S, Shet T, Sridhar E, Gujral S, Banavali S. Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India. Pediatr Blood Cancer 2020;67:e28682. [PMID: 32865865 DOI: 10.1002/pbc.28682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Chauhan P, Gupta A, Mandelia A, Yadav S, Rahman K, Nityanand S. Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience. Pediatr Hematol Oncol 2021;38:305-18. [PMID: 33646922 DOI: 10.1080/08880018.2020.1865493] [Reference Citation Analysis]
66 Erker C, Harker-Murray P, Burke MJ. Emerging immunotherapy in pediatric lymphoma. Future Oncol 2016;12:257-70. [PMID: 26616565 DOI: 10.2217/fon.15.282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Cairo MS, Pinkerton R. Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol 2016;173:507-30. [DOI: 10.1111/bjh.14035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
68 Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, Anderson JR, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol 2019;185:374-7. [PMID: 30117142 DOI: 10.1111/bjh.15520] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
69 Kobos R, Terry W. Advances in therapies for non-Hodgkin lymphoma in children. Hematology 2015;2015:522-8. [DOI: 10.1182/asheducation.v2015.1.522.3916185] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Moleti ML, Al-jadiry MF, Shateh WA, Al-darraji AF, Mohamed S, Uccini S, Piciocchi A, Foà R, Testi AM, Al-hadad S. Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. Leukemia & Lymphoma 2018;60:1224-33. [DOI: 10.1080/10428194.2018.1519810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Giménez-Roca C, Iglesias E, Vicente MA, Bou R, Calzada-Hernández J, Prat C, García M, Antón J. Pediatric cryoglobulinemic vasculitis successfully managed with rituximab. Dermatol Ther 2017;30. [PMID: 27791307 DOI: 10.1111/dth.12430] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Osumi T, Mori T, Fujita N, Saito AM, Nakazawa A, Tsurusawa M, Kobayashi R. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016;63:1794-9. [PMID: 27314926 DOI: 10.1002/pbc.26105] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
73 Zhen Z, Zhu J, Wang J, Lu S, Sun F, Huang J, Sun X. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4. Pediatric Hematology and Oncology 2020;37:489-99. [DOI: 10.1080/08880018.2020.1759741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 Maschan A, Myakova N, Aleinikova O, Abugova Y, Ponomareva N, Belogurova M, Fechina L, Fedorova A, Grigor'eva N, Lebedev V, Nikonova O, Shamardina A, Sharapova G, Smirnova N, Rudneva A, Volchkov E, Samochatova E. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. Br J Haematol 2019;186:477-83. [PMID: 31069789 DOI: 10.1111/bjh.15944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]